JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$3.58B |
| 2 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$2.7B |
| 3 |
Apple
AAPL
|
+$1.71B |
| 4 |
Schwab Short-Term US Treasury ETF
SCHO
|
+$1.57B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.51B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.51B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$920M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$817M |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$794M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.23% |
| 2 | Technology | 15.68% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 9.78% |
| 5 | Healthcare | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
AZUL
4751
DELISTED
Azul
AZUL
| $344K | ﹤0.01% |
13,020
-230,715
| -95% | -$5.51M |
2020 Q3
3 quarters
|
|
|
FOCL
4752
EDAP TMS S.A.
FOCL
$204M
| $344K | ﹤0.01% |
48,499
+38,834
| +402% | +$282K |
2020 Q3
3 quarters
|
|
4753
State Street SPDR S&P China ETF
GXC
$454M
| $344K | ﹤0.01% |
2,590
+1,890
| +270% | +$247K |
2019 Q4
6 quarters
|
|
4754
RPC Inc
RES
$1.27B
| $344K | ﹤0.01% |
69,446
+4,995
| +8% | +$26.9K |
2015 Q4
22 quarters
|
|
4755
RGC Resources
RGCO
$225M
| $344K | ﹤0.01% |
13,639
-11,171
| -45% | -$253K |
2017 Q4
14 quarters
|
|
4756
BlackRock Taxable Municipal Bond Trust
BBN
$890M
| $343K | ﹤0.01% |
13,306
| – | – |
2020 Q4
2 quarters
|
|
4757
United States Natural Gas Fund
UNG
$515M
| $343K | ﹤0.01% |
6,561
-3,276
| -33% | -$140K |
2013 Q2
32 quarters
|
|
|
SGFY
4758
DELISTED
Signify Health, Inc.
SGFY
| $343K | ﹤0.01% |
11,271
-1,070,270
| -99% | -$29.4M |
2021 Q1
1 quarter
|
|
4759
Corbus Pharmaceuticals
CRBP
$123M
| $342K | ﹤0.01% |
6,242
-4,191
| -40% | -$233K |
2017 Q4
14 quarters
|
|
4760
Hurco Companies Inc
HURC
$143M
| $341K | ﹤0.01% |
9,744
-13,788
| -59% | -$480K |
2013 Q2
32 quarters
|
|
4761
OrthoPediatrics
KIDS
$566M
| $341K | ﹤0.01% |
5,377
-12,911
| -71% | -$742K |
2017 Q4
14 quarters
|
|
4762
Red River Bancshares
RRBI
$668M
| $341K | ﹤0.01% |
6,751
-8,608
| -56% | -$467K |
2019 Q2
8 quarters
|
|
|
ENZ
4763
DELISTED
Enzo Biochem, Inc.
ENZ
| $341K | ﹤0.01% |
107,720
-31,552
| -23% | -$99.2K |
2017 Q3
15 quarters
|
|
4764
UFP Technologies
UFPT
$2.28B
| $338K | ﹤0.01% |
5,892
-14,823
| -72% | -$805K |
2017 Q4
14 quarters
|
|
|
DSAC
4765
DELISTED
Duddell Street Acquisition Corp. Class A Ordinary Shares
DSAC
| $338K | ﹤0.01% |
34,868
| – | – |
2020 Q4
2 quarters
|
|
|
CVLY
4766
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $337K | ﹤0.01% |
16,814
-16,342
| -49% | -$307K |
2017 Q4
14 quarters
|
|
4767
Anterix
ATEX
$1.62B
| $335K | ﹤0.01% |
5,597
+115
| +2% | +$5.76K |
2017 Q4
14 quarters
|
|
4768
Syndax Pharmaceuticals
SNDX
$1.63B
| $335K | ﹤0.01% |
19,549
+7,831
| +67% | +$143K |
2016 Q4
18 quarters
|
|
4769
Dyne Therapeutics
DYN
$2.95B
| $334K | ﹤0.01% |
15,848
+5,679
| +56% | +$107K |
2020 Q4
2 quarters
|
|
4770
Relmada Therapeutics
RLMD
$390M
| $334K | ﹤0.01% |
10,442
+1,251
| +14% | +$43.5K |
2020 Q2
4 quarters
|
|
4771
Northern Trust International Quality Dividend ETF
IQDF
$1.13B
| $333K | ﹤0.01% |
12,546
| – | – |
2020 Q4
2 quarters
|
|
4772
Invesco S&P 500 Pure Value ETF
RPV
$1.65B
| $333K | ﹤0.01% |
4,312
+1,710
| +66% | +$134K |
2013 Q2
32 quarters
|
|
4773
Transmedics
TMDX
$2.73B
| $332K | ﹤0.01% |
10,023
-31,885
| -76% | -$884K |
2019 Q2
8 quarters
|
|
4774
TETRA Technologies
TTI
$863M
| $331K | ﹤0.01% |
76,574
+52,357
| +216% | +$172K |
2016 Q4
18 quarters
|
|
4775
Global X SuperDividend US ETF
DIV
$757M
| $330K | ﹤0.01% |
16,540
+11,552
| +232% | +$231K |
2020 Q2
4 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2021 Portfolio in Review
As of Q2 2021, JP Morgan Chase held 6,872 positions worth $838B, up 12% from $749B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase deployed $31.1B of net new capital in Q2 2021, opening 693 new positions and adding to 2,351 existing holdings. Its largest new stake was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 25,313,889 shares worth $358M.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was iShares 20+ Year Treasury Bond ETF, an estimated $1.51B trimmed.
- JP Morgan Chase's largest Q2 2021 buy was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 25,313,889 shares worth $358M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q2 2021, an estimated $3.58B increase.
- JP Morgan Chase's biggest Q2 2021 reduction was iShares 20+ Year Treasury Bond ETF, cutting an estimated $1.51B.
- JP Morgan Chase fully exited INPHI CORPORATION in Q2 2021, selling an estimated $333M.
- JP Morgan Chase's ten largest holdings make up 16% of its $838B portfolio in Q2 2021.
- JP Morgan Chase opened 693 new positions and closed 449 in Q2 2021.
- JP Morgan Chase's portfolio value rose 12% quarter-over-quarter to $838B.
Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.